Alessandro Rossi1, Margherita Ruoppolo2,3, Pietro Formisano4, Guglielmo Villani2,3, Lucia Albano2,3, Giovanna Gallo2,3, Daniela Crisci2,3, Augusta Moccia4, Giancarlo Parenti5,6, Pietro Strisciuglio5, Daniela Melis5. 1. Department of Translational Medical Science, Section of Pediatrics, Federico II University, Via Sergio Pansini, 5, 80131, Naples, Italy. ale.ro_ar@libero.it. 2. Department of Molecular Medicine and Medical Biotechnology, Federico II University, Naples, Italy. 3. CEINGE Biotecnologie Avanzates.c.ar.l., Naples, Italy. 4. Department of Translational Medical Science, Section of Clinical Pathology, Federico II University, Naples, Italy. 5. Department of Translational Medical Science, Section of Pediatrics, Federico II University, Via Sergio Pansini, 5, 80131, Naples, Italy. 6. Telethon Institute of Genetics and Medicine, Pozzuoli, Italy.
Abstract
BACKGROUND: Glycogen storage disease type I (GSDI) is an inborn error of carbohydrate metabolism caused by mutations of either the G6PC gene (GSDIa) or the SLC37A4 gene (GSDIb). GSDIa patients are at higher risk of developing insulin-resistance (IR). Mitochondrial dysfunction has been implicated in the development of IR. Mitochondrial dysfunction can demonstrate abnormalities in plama acylcarnitines (ACs) and urine organic acids (UOA). The aim of the study was to investigate the presence of mitochondrial impairment in GSDI patients and its possible connection with IR. METHODS: Fourteen GSDIa, seven GSDIb patients, 28 and 14 age and sex-matched controls, were enrolled. Plasma ACs, UOA, and surrogate markers of IR (HOMA-IR, QUICKI, ISI, VAI) were measured. RESULTS: GSDIa patients showed higher short-chain ACs and long-chain ACs levels and increased urinary excretion of lactate, pyruvate, 2-ketoglutarate, 3-methylglutaconate, adipate, suberate, aconitate, ethylmalonate, fumarate, malate, sebacate, 4-octenedioate, 3OH-suberate, and 3-methylglutarate than controls (p < 0.05). GSDIb patients showed higher C0 and C4 levels and increased urinary excretion of lactate, 3-methylglutarate and suberate than controls (p < 0.05). In GSDIa patients C18 levels correlated with insulin serum levels, HOMA-IR, QUICKI, and ISI; long-chain ACs levels correlated with cholesterol, triglycerides, ALT serum levels, and VAI. DISCUSSION: Increased plasma ACs and abnormal UOA profile suggest mitochondrial impairment in GSDIa. Correlation data suggest a possible connection between mitochondrial impairment and IR. We hypothesized that mitochondrial overload might generate by-products potentially affecting the insulin signaling pathway, leading to IR. On the basis of the available data, the possible pathomechanism for IR in GSDIa is proposed.
BACKGROUND: Glycogen storage disease type I (GSDI) is an inborn error of carbohydrate metabolism caused by mutations of either the G6PC gene (GSDIa) or the SLC37A4 gene (GSDIb). GSDIa patients are at higher risk of developing insulin-resistance (IR). Mitochondrial dysfunction has been implicated in the development of IR. Mitochondrial dysfunction can demonstrate abnormalities in plama acylcarnitines (ACs) and urine organic acids (UOA). The aim of the study was to investigate the presence of mitochondrial impairment in GSDIpatients and its possible connection with IR. METHODS: Fourteen GSDIa, seven GSDIb patients, 28 and 14 age and sex-matched controls, were enrolled. Plasma ACs, UOA, and surrogate markers of IR (HOMA-IR, QUICKI, ISI, VAI) were measured. RESULTS: GSDIa patients showed higher short-chain ACs and long-chain ACs levels and increased urinary excretion of lactate, pyruvate, 2-ketoglutarate, 3-methylglutaconate, adipate, suberate, aconitate, ethylmalonate, fumarate, malate, sebacate, 4-octenedioate, 3OH-suberate, and 3-methylglutarate than controls (p < 0.05). GSDIb patients showed higher C0 and C4 levels and increased urinary excretion of lactate, 3-methylglutarate and suberate than controls (p < 0.05). In GSDIa patients C18 levels correlated with insulin serum levels, HOMA-IR, QUICKI, and ISI; long-chain ACs levels correlated with cholesterol, triglycerides, ALT serum levels, and VAI. DISCUSSION: Increased plasma ACs and abnormal UOA profile suggest mitochondrial impairment in GSDIa. Correlation data suggest a possible connection between mitochondrial impairment and IR. We hypothesized that mitochondrial overload might generate by-products potentially affecting the insulin signaling pathway, leading to IR. On the basis of the available data, the possible pathomechanism for IR in GSDIa is proposed.
Authors: Timothy R Koves; John R Ussher; Robert C Noland; Dorothy Slentz; Merrie Mosedale; Olga Ilkayeva; James Bain; Robert Stevens; Jason R B Dyck; Christopher B Newgard; Gary D Lopaschuk; Deborah M Muoio Journal: Cell Metab Date: 2008-01 Impact factor: 27.287
Authors: Marieke G Schooneman; Gabriella A M Ten Have; Naomi van Vlies; Sander M Houten; Nicolaas E P Deutz; Maarten R Soeters Journal: Am J Physiol Endocrinol Metab Date: 2015-06-02 Impact factor: 4.310
Authors: Santhosh Satapati; Nishanth E Sunny; Blanka Kucejova; Xiaorong Fu; Tian Teng He; Andrés Méndez-Lucas; John M Shelton; Jose C Perales; Jeffrey D Browning; Shawn C Burgess Journal: J Lipid Res Date: 2012-04-09 Impact factor: 5.922
Authors: Antonia Giacco; Giuseppe Delli Paoli; Roberta Simiele; Marianna Caterino; Margherita Ruoppolo; Wilhelm Bloch; Robert Kraaij; André G Uitterlinden; Alessandra Santillo; Rosalba Senese; Federica Cioffi; Elena Silvestri; Stefania Iervolino; Assunta Lombardi; Maria Moreno; Fernando Goglia; Antonia Lanni; Pieter de Lange Journal: Physiol Rep Date: 2020-02
Authors: Natalia I Krupenko; Jaspreet Sharma; Peter Pediaditakis; Kristi L Helke; Madeline S Hall; Xiuxia Du; Susan Sumner; Sergey A Krupenko Journal: Hum Genomics Date: 2020-11-09 Impact factor: 4.639